Journal Article DKFZ-2026-00426

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
An oBservational retrospective Analysis of treatment patternS and Effectiveness of standard of CAre for Multiple Myeloma Patients Exposed to Lenalidomide and a Proteasome Inhibitor: BasecaMMp Study.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2026
Elsevier Amsterdam [u.a.]

Clinical lymphoma, myeloma & leukemia nn, nn () [10.1016/j.clml.2026.01.013]
 GO

Abstract: Most patients with relapsed or refractory multiple myeloma (RRMM) have previously received lenalidomide (LEN) and proteasome inhibitors (PIs). This real-world study describes treatment patterns and clinical outcomes for RRMM patients post-LEN and PI in Germany.The BasecaMMp cohort included patients with prior LEN and PI therapy within the first to third line of treatment (LOT) between May 2016 and December 2023. Patient characteristics, treatment regimens and progression-free survival (PFS), overall survival (OS) and time to next treatment (TTNT) were analyzed.Of 1834 patients included (median age: 72.5 years; 59.5% male; median of 2 prior LOTs), around 30.4% were double-refractory, and 47.7% were LEN-refractory. Index therapies (first therapies received after exposure to LEN and a PI in the first to third lines) were highly heterogeneous. Median PFS was 12.7 (95% confidence interval [CI], 12.2-13.14) months overall and 11.3 (95% CI, 10.3-12.1) months in LEN-refractory patients, while median OS was 37.1 (95% CI, 34.2-40.7) months overall and 34.3 (95% CI, 31.1-41.0) months in LEN-refractory patients.These findings highlight the lack of a clear standard of care, poor clinical outcomes, and the need for more effective therapies and treatment strategies for this population.

Keyword(s): Outcomes ; Overall survival ; Progression-free survival ; Real-world setting ; Relapsed or refractory multiple myeloma

Classification:

Note: ISSN 2152-2650 / epub

Contributing Institute(s):
  1. DKTK Koordinierungsstelle München (MU01)
Research Program(s):
  1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2026
Database coverage:
Medline ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2026-02-23, last modified 2026-02-23



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)